{"id":"monthly-adx-2191-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Conjunctival injection"},{"rate":null,"effect":"Eye irritation"},{"rate":null,"effect":"Ocular discomfort"}]},"_chembl":{"chemblId":"CHEMBL2108760","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug works by sequestering reactive aldehyde species that accumulate in inflammatory conditions of the eye. By reducing aldehyde-mediated damage and inflammation, ADX-2191 aims to restore ocular surface homeostasis and reduce symptoms associated with dry eye disease and other anterior segment inflammatory conditions. The monthly injection formulation provides sustained local delivery to the eye.","oneSentence":"ADX-2191 is a reactive aldehyde species (RAS) scavenger that binds and neutralizes pathogenic aldehydes implicated in ocular surface inflammation and disease.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:22:03.054Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Dry eye disease"},{"name":"Ocular surface inflammation"}]},"trialDetails":[{"nctId":"NCT07402876","phase":"PHASE3","title":"A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma","status":"RECRUITING","sponsor":"Aldeyra Therapeutics, Inc.","startDate":"2026-02","conditions":"Primary Vitreoretinal Lymphoma","enrollment":20},{"nctId":"NCT05392179","phase":"PHASE2","title":"A Study in Subjects With Retinitis Pigmentosa","status":"COMPLETED","sponsor":"Aldeyra Therapeutics, Inc.","startDate":"2022-07-14","conditions":"Retinitis Pigmentosa","enrollment":8}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3568,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Monthly ADX-2191 injection","genericName":"Monthly ADX-2191 injection","companyName":"Aldeyra Therapeutics, Inc.","companyId":"aldeyra-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aldeyra Therapeutics is conducting clinical trials for ADX-2191, a treatment that has been studied for use in patients with Primary Vitreoretinal Lymphoma and Retinitis Pigmentosa. ADX-2191 is administered via injection, with a monthly dosing frequency being one of the studied interventions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}